AbbVie Inc (LTS:0QCV)
$ 177.49 1.52 (0.88%) Market Cap: 318.09 Bil Enterprise Value: 381.92 Bil PE Ratio: 62.50 PB Ratio: 52.72 GF Score: 85/100

Abbvie Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 02:30PM GMT
Release Date Price: $84.66
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD

Great. Good morning, everybody. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. I'm very pleased to be hosting AbbVie this morning. Joining us from the company, we have Rick Gonzalez, Chairman and CEO; Mike Severino, Vice Chairman and President; and Rob Michael, Executive VP and CFO of the company.

Thank you very much for spending time today with us, everyone, and really appreciate it.

Questions & Answers

Terence C. Flynn;Richard A. Gonzalez
Goldman Sachs Group, Inc., Research Division - MD;

Maybe just to get started at a high level. Obviously, COVID is top of mind for everyone. And in our view, it's going to have near and long-lasting impacts on the health care system and business models if you think about delivery of care, clinical trial conduct and supply chain. So Rick, was just wondering, maybe to start, if you could share any preliminary perspective from where you sit on the ways COVID could shape your business and strategy?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot